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Cognitive reactivity (CR) is a psychological vulnerability marker of depression, whereas response to
acute tryptophan depletion (ATD; a serotonergic challenge procedure) is a biological vulnerability
marker. The aim of this study was to investigate the relationship between these markers. Thirty-nine
remitted depressed patients participated in 2 ATD sessions in a double-blind crossover design. CR,
assessed prior to the ATD sessions, predicted depressive response to high-dose ATD. CR also diminished
the effects of 2 known predictors of ATD response: gender and residual symptoms. Neuroticism and
behavioral inhibition were unrelated to ATD response. CR is associated with an increased sensitivity to
reductions of serotonin concentrations. These findings present a small step toward unifying cognitive and
neurobiological theories of depression.
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Although depressive episodes can be treated with antidepressant
medication, structured forms of psychotherapy, or both (DeRubeis
et al., 2005; Keller, 1999), the rate of recurrence is high (Judd,
Paulus, & Zeller, 1999; Mueller et al., 1999). Identifying individ-
uals at high risk of relapse might improve overall outcome. There
are a number of promising vulnerability markers of depression.
Biological markers include response to pharmacological chal-
lenges such as the dexamethasone/corticotropin releasing hormone
(DEX-CRH) test (Ising et al., 2005) and response to acute trypto-
phan depletion (Moreno, Henninger, McGahuey, & Delgado,
2000). Promising psychological vulnerability markers include cog-
nitive reactivity (Segal, Gemar, & Williams, 1999), rumination
(Kuehner & Weber, 1999), and information-processing indices
(Elliott, 1998).
The impact of biological manipulations on information process-
ing has been investigated in recent studies. Acute tryptophan
depletion, a method that temporarily lowers serotonin (5-
hydroxytryptamine; 5-HT) function (Young, Smith, Pihl, & Ervin,
1985), impaired memory consolidation (Riedel, Klaassen, Deutz,
van Someren, & Van Praag, 1999; Schmitt et al., 2000) and
emotional processing in both healthy volunteers (Harmer, Rogers,
Tunbridge, Cowen, & Goodwin, 2003; Murphy, Smith, Cowen,
Robbins, & Sahakian, 2002; Young et al., 1985) and remitted
depressed patients (Booij, Van der Does, Haffmans, Riedel, et al.,
2005). Improving 5-HT function with the selective serotonin re-
uptake inhibitor (SSRI) citalopram (20 mg/day) over 7 days facil-
itated the recall of positive information but impaired the detection
of facial expressions of anger and fear in healthy volunteers
(Harmer, Mackay, Reid, Cowen, & Goodwin, 2006; Harmer, Shel-
ley, Cowen, & Goodwin, 2004). These findings suggest that both
cognitive and symptomatic changes are part of the same overall
response to 5-HT manipulation and that cognitive changes occur at
a lower threshold, or that they may be two independent effects.
Administration of the 5-HT2 agonist fenfluramine in healthy vol-
unteers improved dysfunctional attitudes without significantly af-
fecting mood (Meyer et al., 2003), suggesting that changes in 5-HT
may activate or deactivate depression-related schemas. Both sero-
tonergic and noradrenergic systems are implicated in the patho-
physiology of depression, and they are the most promising targets
for treatment (Maes & Meltzer, 1995; Morilak & Frazer, 2004).
Manipulations of these neurotransmitter systems, with medication
or experimental challenge procedures, have characteristic effects
on cognition (Booij, Van der Does, & Riedel, 2003); however,
most research has focused on the 5-HT system.
The present study was designed to investigate the relationship
between a serotonergic and a cognitive marker of depression
vulnerability. Although the cognitive effects of biological manip-
ulations have been the subject of some recent research, the rela-
tionship of cognitive vulnerability and biological vulnerability has
not been investigated. In the present study, we focused on a
serotonergic challenge procedure called acute tryptophan deple-
tion (ATD). This procedure temporarily lowers 5-HT function by
depleting its precursor L-tryptophan (Trp). ATD is induced by a
1-day, low-Trp diet, followed by the ingestion of a mixture of all
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essential amino acids (AAs) except Trp (Young et al., 1985). ATD
reduces plasma Trp levels by 75%–90% in 5–7 hr, and central
5-HT function is also impaired (Carpenter et al., 1998; Nishizawa
et al., 1997).
It has often been demonstrated that a high-dose ATD (75–102.5
g AAs) transiently exacerbates symptoms in about 50% of patients
in remission from depression (Van der Does, 2001). The symp-
toms elicited by ATD are specific to depression (Booij, Van der
Does, Haffmans, Spinhoven, & McNally, 2005), and the effects
are largest in patients treated with SSRIs (Delgado et al., 1999).
ATD is a challenge procedure, but patients do not regard the
procedure as problematic (Booij, Van der Does, Haffmans, Spin-
hoven, & McNally, 2005). Furthermore, more than 220 ATD
studies have been published since 1977. These studies involved
more than 3,900 participants, many with a psychiatric disorder,
and no adverse events have been reported. Early research findings
presented ATD as a tool to investigate the mechanism of action of
antidepressant treatment (Delgado et al., 1990), but more recent
research indicates that ATD response not only is related to prior
treatment modality but also reflects individual vulnerability to
depressive relapse. For instance, unmedicated recovered depressed
patients also respond to ATD (Neumeister et al., 2004; Smith,
Fairburn, & Cowen, 1997). Furthermore, gender, chronicity of
depression, and history of suicidal ideation are independent pre-
dictors of depressive response to ATD (Booij et al., 2002). In most
studies, ATD causes no significant changes in mood in healthy
samples. If mood does change significantly in never-depressed
samples, the effect is rather small and is limited to depression-
vulnerable individuals, for example, first-degree relatives of pa-
tients with depression (Benkelfat, Ellenbogen, Dean, Palmour, &
Young, 1994; Klaassen et al., 1999). Finally, preliminary findings
indicate that the response to ATD may predict a recurrence of
depression within 1 year (Moreno et al., 2000; Neumeister, Ha-
beler, Praschak-Rieder, Willeit, & Kasper, 1999). These findings
suggest that response to ATD is a biological vulnerability marker
of depression.
From a cognitive perspective, dysfunctional schemas are a core
vulnerability marker of depression (Beck, 1967). These schemas
are assessed with a self-report scale, the Dysfunctional Attitude
Scale (DAS; Weissman, 1979). However, DAS scores normalize
when depression is in remission, even when cognitions have not
been targeted in treatment (Simons, Garfield, & Murphy, 1984).
Other measures of dysfunctional schemas also covary with clinical
status (Lau, Segal, & Williams, 2004), casting doubt on their
hypothesized etiological role in depression. However, it has been
shown that dysfunctional schemas do not disappear during remis-
sion but become inactive and may be reactivated by relatively mild
(nonpathological) increases of sad mood (Miranda & Persons,
1988; Segal, Williams, Teasdale, & Gemar, 1996: Sheppard &
Teasdale, 2004; Teasdale, 1988). This may trigger a feedback loop
that ends in a recurrence of depression (Lau et al., 2004; Teasdale,
1988).
The extent to which dysfunctional schemas are activated when
mood decreases has been labeled cognitive reactivity (CR). CR can
be assessed in the laboratory by measuring dysfunctional attitudes
before and after a sad mood induction (Miranda, Gross, Persons, &
Hahn, 1998). Euthymic, previously depressed individuals have
higher DAS change scores following a sad mood induction than
never-depressed individuals, despite similar changes in mood
(Miranda et al., 1998; Segal et al., 1999; Van der Does, 2002a). CR
has also been demonstrated with tests of automatic rather than
effortful processes. For instance, using an implicit association test,
Gemar, Segal, Sagrati, and Kennedy (2001) found an increased
negative evaluative bias after a psychological mood induction in
individuals with a history of depression as compared with controls.
The bias after mood induction was comparable to that observed in
individuals with a current depression. High CR also predicted
earlier relapses within 1 to 4 years posttreatment (Segal et al.,
1999; Segal, Kennedy, Gemar, Sagrati, & Hood, 2003).
It has been suggested that CR can be assessed by means of
self-report questionnaires, the Depressed States Checklist (Teas-
dale & Cox, 2001), and the Leiden Index of Depression Sensitivity
(LEIDS; Van der Does, 2002a). The LEIDS uses a similar ap-
proach to another measure of vulnerability to psychopathology, the
Anxiety Sensitivity Index (Peterson & Reiss, 1992). Whereas the
DAS consists of “absolute” statements (e.g., “You can only be
happy if you’re good-looking, rich, and smart”), the LEIDS asks
conditional questions—participants are asked to indicate how their
thinking changes when they feel down (e.g., “When in a sad mood,
I become more bothered by perfectionism”). In four studies,
LEIDS scores distinguished euthymic individuals with and without
a history of depression (Merens et al., 2005; Van der Does, 2002a,
2005; Williams, Van der Does, Barnhofer, Crane, & Segal, 2006).
In the first two of these studies the DAS was also administered and
did not distinguish between groups. The validity of the LEIDS as
a measure of CR is also supported by high correlations with DAS
change scores before and after mood inductions (Van der Does,
2002b) and by a correlation of .58 with the Depressed States
Checklist (Merens et al., 2005). Finally, the hopelessness/
suicidality subscale of the LEIDS1 predicted change in positive
future fluency scores, a behavioral measure of hopelessness (Wil-
liams et al., 2006).
The aim of the present study was to investigate whether indi-
vidual differences in cognitive reactivity to sad mood, as indexed
by the LEIDS, are related to differences in sensitivity to acute
reduction of serotonin concentrations, as indexed by the depressive
response to high-dose ATD. Although no prior study has investi-
gated the relationship between cognitive and biological vulnera-
bility markers in a remitted depressed sample, we expected a
positive relationship between high CR scores and a larger depres-
sive response to ATD, based on the finding that the 5HT2 agonist
fenfluramine improved dysfunctional attitudes in healthy volun-
teers (Meyer et al., 2003). To investigate the specificity of this
relationship, we also investigated the relation between ATD re-
sponse and two more general markers of vulnerability to psycho-
pathology: neuroticism and behavioral inhibition. These dimen-
sions correlate moderately highly with CR (Van der Does, 2002a).
Stewart, Deary, and Ebmeier (2002) found no relationship between
response to ATD and neuroticism. However, this study concerned
healthy individuals who had no history of depression, and ATD
has no significant effect in these samples (Van der Does, 2001).
We hypothesized that CR would correlate more strongly with
response to ATD than neuroticism or behavioral inhibition, be-
cause the latter two are risk factors for negative affective states in
1 The LEIDS can be downloaded at www.dousa.nl/publications
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general (Carver & White, 1994; Stewart et al., 2002), and thus are
nonspecific.
Method
Participants
Forty-five patients in remission from a depressive episode entered the
study. All of the participants were outpatients of a mood disorder clinic.
Inclusion criteria were age between 18 and 65, ongoing treatment with an
SSRI or selective serotonin-noradrenalin reuptake inhibitor (SSNRI) for at
least 4 weeks,2 meeting criteria from the Diagnostic and Statistical Manual
of Mental Disorders, 4th edition (DSM–IV; American Psychiatric Associ-
ation, 1994) for past major depressive disorder, a Hamilton Depression
Rating Scale (HRSD, 17-item version; Hamilton, 1960) score lower than
15 (criteria for partial remission derived from Frank et al., 1991), and a
Montgomery–Asberg Depression Rating Scale (MADRS; Montgomery &
Asberg, 1979) score lower or equal to 17.3 Exclusion criteria were sub-
stance abuse within the last 3 months, psychosis (lifetime), major physical
illness, lactation, and pregnancy. All of the patients took part in one of two
consecutive ATD experiments on the effects of high-dose and low-dose
ATD on neuropsychological functioning (Booij et al., 2006; Booij, Van der
Does, Haffmans, Riedel, et al., 2005). The two ATD experiments differed
in the composition of a neuropsychological test battery but were identical
on all other aspects, including design, procedure, experimenter, research
room, symptom assessments, and duration.
Two patients did not complete the self-report questionnaires at intake
because of a procedural error. Two patients who fulfilled inclusion and
exclusion criteria at intake had elevated MADRS scores on the morning of
the high-dose depletion session. Both scores were above the inclusion
criterion (24 and 19), and these patients had to be excluded. Two patients
did not complete the measurements of the first session because of side
effects (one patient in the high-dose condition, the other patient in the
control, low-dose condition) and did not take part in the second session.
One patient completed all measurements during the high-dose ATD session
but did not conduct the control session because of medical reasons unre-
lated to the experiment. This patient was included in the analyses. The
clinical and demographic characteristics of the final sample are presented
in Table 1. All of the patients were paid €115 (approximately $147) for
participation.
Acute Tryptophan Depletion
On each ATD session, patients received in randomized order either a
102.5-g (high-dose) mixture or a 25.7-g (low-dose) control mixture of large
neutral amino acids (LNAAs) in a natural composition but without Trp.
Patients kept a 24-hr low-Trp diet (160 mg/day) prior to both sessions. The
mixtures stimulate protein synthesis, which requires Trp. Furthermore, Trp
competes with the other AAs for the same transport mechanism into the
brain. The composition of the 102.5-g mixture was identical to the mixture
used by Delgado et al. (1999). The 102.5-g mixture in combination with the
low-Trp diet (high-dose ATD) has been shown to reduce Trp concentra-
tions by approximately 90% and has a reliable depressive effect in a
subgroup of remitted depressed patients (Van der Does, 2001). The 25.7-g
control procedure (low-dose ATD) uses the same diet and the same AA
mixture but one quarter the amount (Krahn et al., 1996). Low-dose ATD
has been shown to reduce Trp concentrations by approximately 40%–50%.
In the present study, low-dose ATD was used as a placebo procedure,
based on the findings that it has no effect on symptoms (Booij, Van der
Does, Haffmans, Spinhoven, & McNally, 2005; Spillmann et al., 2001).
AAs were mixed with cold water (4 °C) to a final volume of 300 ml. Liquid
chocolate syrup was added, and we served the mixtures chilled to improve
the unpleasant taste of some of the AAs. During the ATD sessions, water,
(de)caffeinated coffee, (herbal) tea, orange juice, and protein-poor
( 0.05 g) cookies were allowed in standard amounts. Patients had a
low-Trp lunch 3 hr after drinking the mixture. Although ATD is a chal-
2 As the response to ATD is larger in SSRI-treated patients than in
patients treated with noradrenergic antidepressants (Delgado et al., 1990,
Delgado et al., 1999), we only included patients treated with an SSRI to
prevent a confound of medication use with the investigated variables of
interest.
3 As the MADRS was used to assess depressive response to ATD, the
HRSD was used as an additional screening instrument to prevent bias or an
inflation of the relationship for a measure correlated with itself and because
of its well-defined cutoff score to define partial remission (Frank et al.,
1991). In a sample of 77 outpatients with depression, Mittmann et al.
(1997) derived the following formula: MADRS  1.23  HRSD (17-item
version). Thus, an HRSD score of 14 is equivalent to a MADRS score of
16.92.
Table 1
Clinical and Demographic Characteristics of the Sample (N  39)
Variable
Outcome measure
n M SD SE Range
Men/women 19/20
Mean age in years 46.05 9.88 25–61
Type of medication: SSRI/SSNRI (2 SSRI treatment free for 1 month) 27/12
Mean no. of past episodes 4.38 5.21 1–21
Single episode/recurrent episodes 12/27
Mean duration of last episode (in months)
Single episode 27.75 27.35 4–108
Multiple episodes 8.56 8.95 1–36
Mean duration of remission (in months) 14.69 23.91 1–84
History of suicidal ideation 17
No history of suicidal ideation 22
Baseline MADRS 6.28 0.68 0–15
Baseline HRSD 5.72 0.55 0–13
Note. SSRI  selective serotonin reuptake inhibitor; SSNRI  selective serotonin noradrenalin reuptake inhibitor; MADRS  Montgomery–Asberg
Depression Rating Scale; HRSD  Hamilton Depression Rating Scale. History of suicidal ideation is defined as serious suicidal thoughts or attempt during
past depression(s).
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lenge procedure and may elicit side effects, research suggests that the
procedure can be explained well to participants and that it is not seen as a
negative experience afterward (Booij, Van der Does, Haffmans, Spin-
hoven, & McNally, 2005).
Measures
Diagnosis, baseline characteristics. A trained clinical psychologist
recorded current and past psychiatric diagnoses as well as demographic and
clinical background variables using the Structured Clinical Interview for
DSM–IV (SCID–I; First, Spitzer, Gibbon, & Williams, 1995). All infor-
mation was verified by checking medical records. Residual symptoms
experienced during the past 7 days were assessed with both the MADRS
(baseline MADRS) and the 17-item version of the HRSD (baseline HRSD;
see Footnote 3).
Cognitive reactivity. The LEIDS (Van der Does, 2002a) was used to
assess CR. Participants indicate on 5-point scales (0–4) to what extent
their cognitions change when they experience a low mood. It is explained
in the instructions that low mood does not mean a seriously depressed
mood or true depression, and that the task is “to indicate the extent to which
the statements apply to you when you feel somewhat sad.” The scale has
26 items that cover changes in rumination, hopelessness, aggressive
thoughts, risk taking, and perfectionism (e.g., “When I feel sad, I more
often think that I can make no one happy”; “When in a sad mood, I more
often think about how my life could have been different”; “When I feel
down, I more often feel hopeless about everything”; “When I feel some-
what depressed, I think I can permit myself fewer mistakes”). As noted
earlier, several studies support the validity of the scale as a measure of CR
(Merens et al., 2005; Van der Does, 2002a, 2002b, 2005; Williams et al.,
2006). The mean score of the LEIDS was 24.4 (SD  12.4) in a healthy
population and 36.4 (SD  15) in a previously depressed sample (Van der
Does, 2005).
Personality. Neuroticism was measured with the short version of the
Eysenck Personality Questionnaire—Revised (EPQ–RSS; Eysenck & Ey-
senck, 1991), and behavioral inhibition was measured with the Behavioral
Inhibition Scale (BIS/BAS; Carver & White, 1994). The EPQ–RSS also
measures extraversion, psychoticism, and social desirability. The BIS/BAS
also contains the Behavioral Activation Scale (BAS), with subscales Drive,
Fun Seeking, and Reward Responsiveness.
Symptoms. Residual depressive symptoms before the ATD experiment
were measured with the HRSD (Hamilton, 1960). Symptoms during the
ATD sessions were assessed with the MADRS (Montgomery & Asberg,
1979). As in previous ATD studies (see Booij et al., 2003, for a review),
the clinical interview was used as a state measure, and the sleep item was
not assessed. The MADRS was chosen as outcome variable for response to
ATD in favor of the HRSD as it has been shown to be more sensitive to
change in antidepressant treatment trials (Montgomery & Asberg, 1979). It
is also more focused on the psychological symptoms of depression, as
defined by DSM–IV criteria, than the HRSD (Galinowski & Lehert, 1995).
Procedure
Prior to ATD sessions. After providing written informed consent,
participants were invited to a screening interview that included the SCID–I,
HRSD, MADRS, LEIDS, EPQ–RSS, BIS/BAS, and an interview with a
dietician. Patients also completed a neuropsychological test battery. The
time between the intake and the first ATD session was approximately 1
week.
ATD sessions. During Day 1 of each session, patients consumed pre-
packed low-Trp meals at home. Patients came to the laboratory at 8 a.m. or
9 a.m. of Day 2 (– 1 hr), after an overnight fast. Symptom ratings were
obtained, followed by a blood sample. Next, the ATD drink was consumed
(0 hr). For the next 4.5 hr, patients remained in a private research room.
Neutral videos and magazines were available. At  5.25 hr patients
completed a neuropsychological test battery (not described here). A blood
sample was taken at  6 hr. Symptoms were assessed at  6.5 hr. Before
participants went home at  7.25 hr, they received a sandwich or a
Trp-enriched snack and were instructed to resume their regular meals.
Symptom ratings and a blood sample were taken the next morning (t  24
hr). This procedure was repeated at least 1 week later; those who had
received high-dose ATD received the control mixture and vice versa. The
study was conducted in a counterbalanced double-blind randomized cross-
over design. An independent, nationally certified medical ethics committee
approved the study, and all patients provided written informed consent
after the study had been fully explained.
Statistical Analyses
Univariate and multivariate general linear models and correlations were
used to explore relationships between CR and clinical and demographic
variables. We conducted hierarchical multiple regression analyses to pre-
dict response to ATD from CR scores. The dependent variable for the
regression analyses was the depressive response during high-dose ATD
(MADRS, t6.5 – t–1). As gender, recurrent depression, and suicidal
tendencies during previous episodes have been shown to be independent
predictors of response to ATD (Booij et al., 2002), these variables were
reevaluated and forced into the regression equation in case of replicated
significance. Next, to investigate the unique contribution of cognitive
reactivity and neuroticism and keeping the ratio of sample size and number
of predictors under control, we included neuroticism, behavioral inhibition,
and cognitive reactivity in the next step of the analysis. We chose to
preselect variables based on prior research in favor of selecting those
variables in the present data set that correlated highly with ATD response,
because this will minimize the chances of a sample-specific regression
equation (Stevens, 1996). To further correct for inflated probability of a
Type I error and capitalizing on chance, the semipartial correlation of a
predictor with the dependent variable in this analysis had to have a p value
of .016 or less (.05/number of predictors entered) to be entered into the
regression equation, and its contribution was removed if the p value
exceeded .033 (.10/number of predictors entered stepwise). To investigate
the influence of the low-dose ATD, we reran all analyses using mood
change in that condition as the dependent variable. Finally, to evaluate
whether the predictive ability of CR is stronger in the high-dose than the
low-dose condition, we carried out a repeated measures regression follow-
ing the procedure described in Cohen and Cohen (1983). Dose (high dose
vs. low dose) and its interaction with CR were included as predictor
variables, with mood change (either during high dose or low dose) as the
dependent variable. Additional analyses are described below. Regression
models were considered significant if the p value was .05 or less. We
evaluated stability and generalizability of the regression model with the
best fit by using multicollinearity diagnostic tests and a leave-one-out
(“jackknife”) procedure. Post hoc power calculations were also done (Co-
hen, Cohen, West, & Aiken, 2003). Statistical analyses were conducted by
means of SPSS 11.5 on a Windows computer.
Results
Relation Between Clinical and Demographic
Characteristics and CR
Mean LEIDS scores were 36.8 (SEM 1.9; Cronbach’s   .78
in the present sample). For neuroticism and behavioral inhibition,
the means were 6.4 (SEM  0.6; Cronbach’s   .84) and 21.2
(SEM  0.6; Cronbach’s   .78), respectively. Univariate anal-
ysis of variance showed that women tended to have higher LEIDS
scores than men (M  40.2, SEM  1.7 vs. M  33.2, SEM 
3.3), F(1, 37)  3.8, p  .06. LEIDS scores correlated with
neuroticism (r  .40, p  .01) and BIS (r  .44, p  .005) and
89COGNITIVE AND SEROTONERGIC VULNERABILITY
moderately with MADRS baseline (r  .29, p  .09). After
partialing out the effect of gender, LEIDS correlated significantly
with BIS (r  .36, p  .03) and moderately with neuroticism (r 
.31, p .06) but not with MADRS baseline (r .19, p .25). No
other clinical or demographic correlates with LEIDS scores were
found before or after correcting for a gender difference ( p  .11).
Mood, Biochemical Effects of ATD
High-dose ATD reduced total Trp and total Trp/LNAA by
86.0% (SEM  0.76) and 93.2% (SEM  0.6), respectively.
Reductions in the control condition were 48.5% (SEM  2.5) for
total Trp and 45.6% (SEM  2.9) for total Trp/LNAA. The
differences between the conditions were significant, F(1, 35) 
245.0, p  .001 for Trp and, F(1, 35)  277.0, p  .001, for ratio
total Trp/LNAA. Thus, the intervention had the intended biochem-
ical effects. Symptoms on the MADRS scale increased signifi-
cantly during high-dose depletion session from 4.8 (SEM 0.6) at
t
–1 to 9.1 (SEM  1.2) at t6.5. MADRS scores in the low-dose
condition changed nonsignificantly from 4.4 (SEM  0.7) at t
–1 to
4.7 (SEM  0.7) at t6.5, and the Intervention  Time interaction
was significant, F(1, 37)  14.8, p  .001. There were no order
effects, as shown by a nonsignificant Intervention  Time 
Order interaction, F(1, 37)  0.00, p  1.00.
Predictors of Depressive Response to ATD
Preselection of variables: Clinical and demographic predictors
of response. On the basis of the literature (Booij et al., 2002), we
evaluated the influence of recurrent depression (1 episode vs.  1
episode), gender, and history of suicidal ideation on ATD response
to preselect variables other than CR, neuroticisms, and inhibition
to include in the analysis. Regression analysis showed that re-
sponse was larger in women than in men (M 5.9, SEM 1.1 vs.
M 2.8, SEM 1.0), F(1, 37) 4.5, p .04. None of the clinical
and demographic factors mentioned in Table 1 were related to
ATD response after partialing out the contribution of gender ( p 
.11). The difference in depressive response could not be explained
by differences in reduction of Trp levels, F(1, 38) 1.39, p .71,
or ratio Trp/LNAAs, F(1, 38)  0.34, p  .56. Therefore, only
gender was included in the analyses below.
Cognitive reactivity, neuroticism, behavioral inhibition, and
ATD response (Table 2, Model 1). The signs of the regression
coefficients (B) indicate that being female (Model 1, Step 1)
predicts a larger depressive response to ATD. The unique contri-
bution of gender was reduced to a nonsignificant level when CR
entered the analysis (Model 1, Step 2). The stepwise analysis did
not allow neuroticism or behavioral inhibition to enter the model,
as both predictors were not significant ( p  .80 and p  .81,
respectively). To investigate whether CR had significant unique
effects above and beyond those of neuroticism and behavioral
inhibition, we forced the latter mentioned variables into the equa-
tion, followed by an evaluation of the additional effects of CR, if
any. A model with neuroticism and BIS but without CR was not
significant (R2  .06), F(2, 36)  1.22, p  .31. Adding CR
increased multiple R to .46 (R2  .21), F(1, 35)  6.37, p  .016,
and the contribution of CR was significant ( p  .016). In both
models with and without CR, the contribution of neuroticism and
BIS were not significant ( p  .86).
Thus, CR predicted depressive response to ATD above and beyond
other investigated demographic and clinical variables. Zero-order
correlations with ATD response were .46 ( p .004) for CR, .22 ( p
.19) for neuroticism, and .24 ( p  .14) for behavioral inhibition.
Cognitive reactivity, residual symptoms, and ATD response
(Table 2, Model 2). As residual symptoms (assessed during the
intake session and indicated by baseline MADRS) and CR corre-
lated moderately (see above), we investigated whether the effect of
CR remained significant after residual symptoms were entered into
the model. Baseline MADRS score was entered first (Model 2,
Step 1), followed by CR (Model 2, Step 2). In the two-predictor
model, only the contribution of CR was significant. A combined
model, entering gender and residual symptoms first, followed by
CR, also showed that CR was the only significant predictor (Table
3). Similar results were obtained when baseline HRSD instead of
baseline MADRS was used in the analysis. Finally, we wanted to
evaluate whether the effect of CR was still significant when all the
other variables that correlated with ATD were partialed out. A
hierarchical regression analysis in which all other variables that
correlated with ATD response were entered first (gender, residual
symptoms, suicidality), followed by CR, showed that CR was the
only significant predictor ( p  .05).4
4 As the two-predictor model—cognitive reactivity, corrected for resid-
ual symptoms—was the most parsimonious model with the best fit, gen-
eralizability of this model was further investigated. The multicollinearities
among the predictors’ residual symptoms and CR were low (variance
inflation factor  1.09; tolerance level  0.92; range condition index 
1.00–7.75). Influence diagnostics were further investigated according to
the procedure described in Stevens (1996): for Cook’s D, range  0.00–
0.13; DFBETA, range  –0.019–0.024 (LEIDS) and –0.056–0.05 (re-
sidual symptoms); Mahalonobis distances, range  0.03–8.90 (critical
value  11.44; Stevens, 1996, p. 115); ZRESID (standardized residual),
Table 2
Summary of the Hierarchical Regression Analyses for Variables
Predicting ATD Response (N  39)
Variable B SE B  p ()
Model 1
Step 1
Gender 3.11 1.47 .33 .04
Step 2
Gender 1.98 1.44 .21 .18
LEIDS 0.16 0.06 .39 .01
Model 2
Step 1
Baseline MADRS 0.44 0.17 .39 .01
Step 2
Baseline MADRS 0.32 0.17 .29 .06
LEIDS 0.15 0.06 .37 .016
Note. Model 1: R2  .11, adjusted R2  .08 for Step 1; R2  .14,
adjusted R2  .20 for Step 2, p  .01 for Step 2. Model 2: R2  .15,
adjusted R2  .13 for Step 1; R2  .13, adjusted R2  .24, p  .01 for
Step 2. ATD  acute tryptophan depletion; MADRS  Montgomery–
Asberg Depression Rating Scale; LEIDS  Leiden Index of Depression
Sensitivity.
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To explore the relationship between ATD response and other
personality characteristics, we calculated post hoc correlations
between ATD response and the other subscales of the EPQ, in-
cluding extraversion, psychoticism, and social desirability; be-
tween ATD response and the sum score of the BAS; and between
ATD response and the scores of the individual subscales of the
BAS (reward responsiveness, fun seeking, and drive). None of the
correlations, however, were significant (r  .22, p  .19).
Effects in the Control Condition, Side Effects
The correlation between change in symptoms during high-dose
ATD and CR changed from .46 ( p .004) to .47 ( p .004) when
the change in symptoms during the control condition was partialed
out. An additional post hoc analysis of the low-dose condition in
the present study showed that there were no correlations between
low-dose ATD response and CR (r  –.16, p  .32). To investi-
gate potential relationships further, we reran regression analysis as
described in the section about mood and biochemical effects,
except that the change in symptoms following high-dose condition
was replaced by the change in symptoms in the control condition.
None of the regression models predicted symptom change in the
control condition to a statistically significant degree ( p  .10).
Finally, to test whether the predictive ability of CR is stronger in
the high-dose than in the low-dose condition, we conducted a
repeated measure multiple regression following the procedure of
Cohen and Cohen (1983). Dosage (low dose vs. high dose) and its
interaction with CR were included as predictors in the regression
analysis; symptom change was the dependent variable. The inter-
action between dose and CR was the only significant predictor (t
3.19, p  .002; B  .19 [SE  .06];   .77). The sign of the beta
coefficients indicated that CR predicted mood response to ATD,
but only in the high-dose condition. Similar results were obtained
when residual symptoms were also included as a predictor.
Discussion
The present study shows that patients in remission from depres-
sion who score highly on a psychological vulnerability index are
more affected by the experimental lowering of serotonin than
remitted depressed patients with low CR scores. Evidence to
support the predictive power of CR was derived from several
regression models and stability coefficients. Discriminant validity
was further supported by the findings that neuroticism and behav-
ioral inhibition were unrelated to ATD response, and neither were
other personality characteristics as measured by the EPQ and
BIS/BAS scales. Residual symptoms or other clinical factors did
not explain the results. As in previous studies, ATD response was
higher in women than in men (Booij et al., 2002; Booij, Van der
Does, Haffmans, Spinhoven, & McNally, 2005; Ellenbogen,
Young, Dean, Palmour, & Benkelfat, 1996); however, the gender
difference in the present study was no longer significant when CR
entered the equation. No previous ATD studies have assessed CR.
The present study suggests that relatively large cognitive changes
in response to small (nonpathological) changes in mood (i.e., CR)
are an independent predictor of symptomatic changes in response
to at least one biological challenge.
Sheppard and Teasdale (2000, 2004) suggested that there are
two sources of dysfunctional thoughts in depression: (a) increased
access to dysfunctional schemas and (b) decreased monitoring of
the thoughts and feelings that are the products of these schemas
(reduced “metacognitive monitoring”). Their work suggests that
patients with depression have a deficit in metacognitive monitor-
ing as well as increased schema accessibility compared with con-
trols (Sheppard & Teasdale, 2000). Remission is accompanied by
improved metacognitive monitoring (e.g., better ability to control
negative thoughts); however, accessibility of schemas is still in-
creased (Sheppard & Teasdale, 2004). Thus, in the course of
remission, controlled processing of dysfunctional thoughts im-
proved, but the increased access to schemas remained during
periods of nonpathological low mood, which increases the risk of
a new episode (Sheppard & Teasdale, 2004). Improved scores on
the DAS may reflect improved metacognitive monitoring rather
than reduced access to dysfunctional schemas. The LEIDS, how-
ever, consists of state-specific questions concerning the thoughts
during a period of low mood. Thus, the LEIDS probably measures
access to dysfunctional schemas during low mood rather than
metacognitive monitoring, and only the actual access may repre-
sent a trait marker for enhanced susceptibility to depression, rather
Table 3
Summary of the Hierarchical Regression Analyses for Variables
Predicting ATD Response (N  39)
Variable B SE B  p ()
Model 3
Step 1
Gender 0.99 0.77 .21 .21
Baseline MADRS 0.35 0.18 .31 .06
Step 2
Gender 0.62 0.75 .13 .42
Baseline MADRS 0.28 0.18 .24 .13
LEIDS 0.14 0.06 .34 .03
Note. R2  .19, adjusted R2  .15 for Step 1; R2  .10, adjusted R2 
.23 for Step 2, p  .01 for Step 2. ATD  acute tryptophan depletion;
MADRS  Montgomery–Asberg Depression Rating Scale; LEIDS 
Leiden Index of Depression Sensitivity.
range  –1.90–3.03. Five percent (n  2) of the participants had a
ZRESID  2, supporting the appropriateness of a linear model. One
participant had relatively high leverage value (0.23; critical value  0.15;
Stevens, 1996). Other influence diagnostics were normal for this partici-
pant (Cook’s D  0.03; Mahalonobis distance  8.90; ZRESID  0.46).
Generalizability of the model was further evaluated by means of a
leave-one-out procedure, using N – 1 participants. The mean standardized
regression coefficients () for the N regression analysis were 0.29 for
residual symptoms (range  0.24–0.37) and 0.37 for CR (range  0.32–
0.42). The mean multiple correlation coefficients (R) varied from 0.49 to
0.59 (M  0.53). Hence, the differences between the values obtained with
N – 1 participants and the model described in Table 2 were quite small,
indicating that the model has good cross-validity power. In all regression
analyses, CR significantly predicted ATD response ( p  .05) except for
one regression model in which CR had a p value of .05. P values for
residual symptoms ranged from .06 to .10 and were .05 in 4 of the 39
regression analyses.
Effect sizes and power for the two-predictor model (residual symptoms,
CR) were calculated by a method described in Cohen et al. (2003). Using
the expected population R2 of . 24, the estimated effect size ( f 2) was .32.
The power was .88 at   .05 and .69 at   .01.
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than a state factor depending on mood or clinical status. Indeed,
LEIDS scores in the present study were similar to those reported in
previous studies of fully recovered unmedicated depressed patients
(Van der Does, 2005).
A possible mechanism underlying the association between CR
and response to ATD may be that both markers reflect chronicity
of illness and, consequently, vulnerability to relapse. Although the
present study found no significant relationship between recurrent
depression and response to ATD, recurrent depression was the
most powerful predictor of ATD response in a previous study
(Booij et al., 2002). Other ATD studies also support this associa-
tion (Neumeister et al., 2004; Smith et al., 1997). The present
sample, however, was relatively chronic. Most patients (70%) had
experienced multiple episodes, and patients with only a single
episode tended to have had long episodes (M  27.7 months,
range  4–108). Hence, we could not make a clear distinction
between a chronic and a nonchronic group. CR has been found to
predict relapse 1–4 years after treatment discontinuation, irrespec-
tive of treatment modality (Segal et al., 1999; Segal et al., 2003).
Also, a small change of dysfunctional cognitions during acute
treatment predicted a shorter time to relapse during a follow-up
period (Beevers, Keitner, Ryan, & Miller, 2003).
The validity of our conclusion that CR predicts response to ATD
is highly dependent on the validity of the LEIDS as a measure of
CR. The validity of the scale has been supported by studies
showing that LEIDS scores predict CR as measured with mood
inductions (Van der Does, 2002a, 2002b; Williams et al., 2006).
As mentioned earlier, it is of interest that the LEIDS score of our
relatively chronic, mostly medicated, and (partially) remitted de-
pressed outpatient group was quite similar to that of unmedicated
fully recovered ex-patients (Van der Does, 2005), whereas their
baseline depression scores were different. This suggests that CR,
as assessed by the LEIDS, represents a trait marker of suscepti-
bility to depression rather than a state factor depending on mood or
clinical status.
Dysfunctional cognitions in response to low mood and depres-
sive response to ATD may be brought about by similar underlying,
presumably serotonergic mechanisms. Positron emission tomogra-
phy (PET) studies examining brain glucose metabolism or cerebral
blood flow found decreased activity in the medial orbitofrontal
cortex in remitted, SSRI-treated patients who responded to ATD
(Bremner et al., 1997; Smith, Morris, Friston, Cowen, & Dolan,
1999). Comparable changes in regional brain activity were ob-
served after a psychological mood induction in currently depressed
and in remitted depressed patients but not in controls without a
history of depression (Liotti, Mayberg, McGinnis, Brannan, &
Jerabek, 2002). Upregulated 5-HT2 receptors and increased 5-HT2
binding potential have been associated with higher dysfunctional
cognitions in depressed patients (Meyer et al., 2003) and with
increased 5-HT transporter binding potential in the prefrontal
cortex, anterior cingulate, thalamus, caudate, and putamen, using
carbon 11-labeled DASB PET (Meyer et al., 2004). In healthy
samples, ATD decreased 5-HT2 receptor binding without changing
mood (Yatham et al., 2001), and there is indirect evidence that
patients who respond to ATD may fail to downregulate 5-HT2
receptors (Yatham et al., 2001). Abnormal regulation of 5-HT2
receptors may be a common underlying mechanism for CR and
ATD response. This hypothesis could be tested in PET studies
combining a 5-HT agonist and ATD in remitted depressed patients.
Because we did not include biological challenges other than
ATD, it could be argued that CR simply predicts response to any
manipulation that effectively elicits depressive symptoms. Addi-
tional research is necessary to see if the relationship between CR
and serotonergic manipulations is specific.
Two types of control conditions are used in the ATD literature.
In the procedure most commonly used, 2.3 g Trp is added to the
high-dose mixture. It should be pointed out that neither this pro-
cedure nor the low-dose procedure that we used is biochemically
inactive but can still be used as control conditions as they do not
induce any symptoms (see Van der Does, 2001). Low-dose ATD
causes similar amounts of side effects as high-dose ATD (Booij,
Van der Does, Haffmans, Spinhoven, & McNally, 2005; Krahn et
al., 1996), and participants were unable to distinguish between the
mixtures when given in a crossover design (Krahn et al., 1996).
Unfortunately, we measured side effects at the point of maximum
depletion rather than shortly after intake of the AA mixture, when
side effects are probably highest.
The absence of a healthy control group without a history of
depression does not limit the interpretation of our findings, be-
cause a depressive response to ATD in never-depressed individu-
als is quite rare. When effects do occur, these are small and limited
to high-risk groups, for example, relatives of depressed patients
(Benkelfat et al., 1994; Klaassen et al., 1999), in particular those
with the 5-HT transporter gene polymorphism of the s/s subtype
(Neumeister et al., 2002). Nevertheless, it would be interesting to
investigate the relationship between CR and 5-HT function in
these high-risk groups. Furthermore, because ATD also produces
depression-congruent cognitive changes (Booij et al., 2005; Mur-
phy et al., 2002), it would be of interest to investigate whether CR
is also related to these ATD-induced cognitive changes. Finally,
future studies could investigate whether CR scores and response to
ATD predict actual relapse of depression and whether different
treatment modalities have a different impact on these vulnerability
markers.
In conclusion, the present findings show that cognitive reactivity
to sad mood predicts depressive symptom response to a 5-HT
challenge in depressed patients in remission. In other words, latent
depressive schemas are related to a greater sensitivity to a reduc-
tion of 5-HT. These findings present a small step toward unifying
cognitive and neurobiological theories of depression.
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